Core Insights - ALK has appointed Edward Jordan as the new Executive Vice President and head of Commercial Operations in North America, effective January 5, 2026, succeeding Søren Niegel [1] - The elevation of ALK's two key commercial regions, Europe and North America, into the Executive Leadership Team aims to strengthen the execution of ALK's Allergy+ strategy [1] Company Overview - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma, manufacturing and marketing allergy immunotherapy treatments and acute anaphylaxis treatments [5] - The company is headquartered in Hørsholm, Denmark, employs around 2,800 people worldwide, and is listed on Nasdaq Copenhagen [5] Leadership Background - Edward Jordan brings over 30 years of biopharmaceutical experience, with expertise in allergy and immunology, having worked with companies like Merck, Teva Pharmaceuticals, and DBV Technologies [2] - His experience includes leading commercial strategy, product launches, and market development, particularly in the North American market [2] Strategic Focus - President & CEO Peter Halling emphasized the importance of strong commercial execution following recent product launches, highlighting Jordan's extensive experience in commercial growth and market insights [3] - Jordan expressed his commitment to strengthening commercial execution to expand access and adoption of ALK's products across North America [3] Executive Leadership Team Composition - Following the appointment of Edward Jordan, the Executive Leadership Team now includes various executives responsible for different operational areas, reinforcing the company's strategic focus [7]

Core Insights - ALK has decided to elevate its key commercial regions, Europe and North America, into the Executive Leadership Team (ELT) to enhance the execution of its Allergy+ strategy [1][2][3] Group 1: Leadership Changes - Effective October 1, 2025, Europe and North America will have direct representation in the ELT, with Dr. Flora Beiche-Scholz becoming the Executive Vice President (EVP) for Commercial Operations in Europe [2] - Søren Niegel will continue as the interim EVP for North America until a permanent replacement is found, after which he will leave the company by mutual agreement [2][5] Group 2: Strategic Focus - The execution of the Allergy+ strategy is progressing well, with new product launches and market expansion being key components [3] - The company is focusing on the differences in market size, opportunities, and challenges between the two regions to optimize its strategy [3] Group 3: Leadership Background - Dr. Flora Beiche-Scholz has been with ALK since 2012 and has significantly transformed the German market, making it ALK's largest market globally [4] - Søren Niegel has contributed to reshaping ALK's global sales and marketing operations since 2012, playing a key role in establishing SLIT-tablets as a standard treatment for severe respiratory allergies [5][6] Group 4: Executive Leadership Team Composition - Following the changes, the ELT will include key executives such as Peter Halling (President & CEO), Claus Steensen Sølje (EVP & CFO), and others, with Flora Beiche-Scholz and Søren Niegel in their respective roles [8]